Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
CareDx, Inc. (CDNA) announced a webinar in collaboration with the National Kidney Foundation and Honor the Gift Coalition to assist kidney transplant patients with Medicare enrollment related to the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020, effective January 1, 2023. The webinar, titled "2023 Medicare Immunosuppressant Coverage: What Patients Need to Know," will take place on October 27, 2022, covering patient eligibility and coverage options. CareDx's initiative reflects its commitment to improving patient access to essential immunosuppressive treatments.
CareDx, Inc. (NASDAQ: CDNA) has announced its sponsorship at the 48th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Las Vegas from October 24-28. The company will present its innovative NGS HLA typing kits and chimerism monitoring solutions. CEO Reg Seeto emphasized their commitment to driving transplantation innovation. Key presentations include the unique hybrid capture approach of AlloSeq Tx17 for better donor-recipient matching, enhancing long-term allograft survival rates. The event highlights CareDx's leadership in precision medicine for transplant patients.
CareDx, Inc. (NASDAQ: CDNA) will host a symposium at the Heart Failure Society of America Annual Scientific Meeting in Washington, D.C., from September 30 to October 3, 2022. The event will focus on innovations in post-cardiac transplant care, particularly the AI Heart Platform with AiCAV™ for assessing cardiac allograft vasculopathy risk. Key presentations will address heart transplant surveillance and predictive models for patient outcomes. CareDx, a leader in precision medicine for transplant patients, emphasizes early interventions to enhance graft and recipient health.
CareDx, Inc. (NASDAQ: CDNA) announced a new study confirming that AlloMap, the only gene-expression profiling blood test for heart transplant rejection, significantly reduces pain and adverse events compared to heart biopsy. Conducted at Baylor University Medical Center, the study involved 43 patients and demonstrated that AlloMap's home testing option minimizes infection risk. The test has been FDA cleared since 2005 and is used in over 90% of U.S. heart transplant centers. The results support CareDx's commitment to enhancing patient experiences in transplant care.
Summary not available.
CareDx, Inc. (Nasdaq: CDNA) is set to host its annual digital health user conference, MEET, from September 18-20 in Las Vegas, Nevada. The event will gather professionals from transplant administration and healthcare to discuss innovations and best practices in transplant operations, patient management, and health equity. CEO Reg Seeto emphasized CareDx's commitment to patient-centered digital health solutions. Innovations such as the AlloCare mobile health app will be showcased, integrating various tools to streamline patient care processes.
Summary not available.
CareDx, Inc. (CDNA) announced its participation in the 29th International Congress of The Transplantation Society (TTS 2022) from September 10-14 in Buenos Aires, Argentina. Over 25 abstracts will be presented, showcasing the clinical applications of AlloSure® donor-derived cell-free DNA and AlloSeq cfDNA, including innovations in transplantation and artificial intelligence. CEO Reg Seeto emphasized the importance of this global presence, while Dr. Alexandre Loupy discussed AI's role in enhancing patient care. The announcement includes forward-looking statements regarding the potential benefits and risks associated with the event.
CareDx, Inc. announced its partnership with MOTTEP for a panel discussion aimed at tackling health disparities in organ transplantation, scheduled for August 18, 2022. The event will highlight the urgent need for improved health equity within organ donation, especially in minority communities, coinciding with National Minority Donor Awareness Month. Panelists include leading experts in the field, including Reg Seeto and Dr. Clive Callender. The discussion aims to raise awareness of the over 100,000 individuals awaiting organ transplants in the U.S., with a focus on high-risk, underserved populations.
CareDx, Inc. (Nasdaq: CDNA) reported its Q2 2022 financial results, achieving revenues of $80.6 million, up 9% year-over-year. The company delivered 45,000 patient test results, reflecting a 21% growth compared to Q2 2021. Despite a net loss of $21.7 million, the company boasts a strong capital position with $306 million in cash and no debt. CareDx revised its 2022 revenue guidance to $325 million to $335 million, attributing growth to an increased mix of commercial patients.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
